Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? 1996

A A Nierenberg, and J A Pava, and K Clancy, and J F Rosenbaum, and M Fava
Depression Research Program, Massachusetts General Hospital Consolidated Department of Psychiatry, Harvard Medical School, Boston, MA 02114, USA.

Few data exist that assess the presence of reversed and positive neurovegetative symptoms through successive depressive episodes. To assess the stability of depressive symptoms across episodes, we studied 74 outpatients with atypical unipolar major depression, diagnosed by the Structured Clinical Interview for DSM-III-R, before response to fluoxetine treatment and again after relapse on either fluoxetine or placebo. Patients were assessed at baseline with the Atypical Depression Diagnosis Scale and at baseline and during follow-up with the 17-item Hamilton Rating Scale for Depression. Thirty-two (43%) of responders had a relapse or recurrence, 21 (66%) of whom had a predominance of reversed of positive neurovegetative symptoms at baseline. Nine of 10 (90%) patients with reversed symptoms at baseline had the same symptoms when they relapsed; seven of 11 (64%) of those with positive symptoms at baseline had positive symptoms again (kappa 0.557). Overall, five of 21 (24%) had changes in their disturbances in sleep, appetite, or weight when they relapsed. This study supports the relative stability of neurovegetative symptoms in atypical depression across episodes.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010555 Personality Inventory Check list, usually to be filled out by a person about himself, consisting of many statements about personal characteristics which the subject checks. Edwards Personal Preference Schedule,Myers-Briggs Type Indicator,Indicator, Myers-Briggs Type,Inventories, Personality,Inventory, Personality,Myers Briggs Type Indicator,Personality Inventories
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D005473 Fluoxetine The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. Fluoxetin,Fluoxetine Hydrochloride,Lilly-110140,N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine,Prozac,Sarafem,Lilly 110140,Lilly110140
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

A A Nierenberg, and J A Pava, and K Clancy, and J F Rosenbaum, and M Fava
October 1990, Journal of affective disorders,
A A Nierenberg, and J A Pava, and K Clancy, and J F Rosenbaum, and M Fava
April 2019, CNS spectrums,
A A Nierenberg, and J A Pava, and K Clancy, and J F Rosenbaum, and M Fava
April 1997, The American journal of orthopsychiatry,
A A Nierenberg, and J A Pava, and K Clancy, and J F Rosenbaum, and M Fava
July 2003, Fortschritte der Neurologie-Psychiatrie,
A A Nierenberg, and J A Pava, and K Clancy, and J F Rosenbaum, and M Fava
January 2017, Movement disorders clinical practice,
A A Nierenberg, and J A Pava, and K Clancy, and J F Rosenbaum, and M Fava
January 2004, General hospital psychiatry,
A A Nierenberg, and J A Pava, and K Clancy, and J F Rosenbaum, and M Fava
January 1985, Journal of affective disorders,
A A Nierenberg, and J A Pava, and K Clancy, and J F Rosenbaum, and M Fava
March 2014, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
A A Nierenberg, and J A Pava, and K Clancy, and J F Rosenbaum, and M Fava
January 2001, Comprehensive psychiatry,
A A Nierenberg, and J A Pava, and K Clancy, and J F Rosenbaum, and M Fava
March 1999, International psychogeriatrics,
Copied contents to your clipboard!